Cargando…
Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
As a genetic disease, there has been a long-standing effort to identify therapeutic options for autosomal dominant polycystic kidney disease (ADPKD). Following the development of tolvaptan, a vasopressin 2 receptor antagonist, the treatment strategy for ADPKD patients with rapid disease progression...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175869/ https://www.ncbi.nlm.nih.gov/pubmed/37089056 http://dx.doi.org/10.3904/kjim.2022.376 |